Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Short

Showing results (201-210 of 346) with videos related to

Pageof 35
Sort By:
Cancers|January 11, 2022
Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaAmber Gibson, Adriana Trabal, David McCall, et al.
Blood Cancer Journal|January 26, 2022
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapySangeetha Venugopal, Koichi Takahashi, Naval Daver, et al.
Blood Advances|January 24, 2025
TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantationKonstantinos Lontos, Rima M Saliba, Rashmi Kanagal-Shamanna, et al.
Journal of Hematology & Oncology|November 16, 2024
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosisSamuel Urrutia, Hagop M Kantarjian, Farhad Ravandi-Kashani, et al.
American Journal of Hematology|May 17, 2026
Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALLSankalp Arora, Hagop Kantarjian, Koji Sasaki, et al.
Cancer|March 9, 2023
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulationDaniel Nguyen, Hagop M Kantarjian, Nicholas J Short, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 9, 2026
Comprehensive Cytogenomic Profiling of T-Lymphoblastic Leukemia by Optical Genome Mapping, Karyotyping and Next Generation SequencingGuilin Tang, Alexandra Reynolds, Farhad Ravandi-Kashani, et al.
American Journal of Hematology|December 24, 2024
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic DesignationJayastu Senapati, Hagop M Kantarjian, Fadi G Haddad, et al.
American Journal of Hematology|April 12, 2022
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsKunhwa Kim, Marina Konopleva, Courtney D DiNardo, et al.
Cancer|July 13, 2021
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclaxKunhwa Kim, Abhishek Maiti, Sanam Loghavi, et al.
Pageof 35

Showing results (201-210 of 346) with videos related to

Sort By:
Pageof 35
Cancers|January 11, 2022
Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaAmber Gibson, Adriana Trabal, David McCall, et al.
Blood Cancer Journal|January 26, 2022
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapySangeetha Venugopal, Koichi Takahashi, Naval Daver, et al.
Blood Advances|January 24, 2025
TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantationKonstantinos Lontos, Rima M Saliba, Rashmi Kanagal-Shamanna, et al.
Journal of Hematology & Oncology|November 16, 2024
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosisSamuel Urrutia, Hagop M Kantarjian, Farhad Ravandi-Kashani, et al.
American Journal of Hematology|May 17, 2026
Predictors of Relapse and Post-Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome-Negative B-ALLSankalp Arora, Hagop Kantarjian, Koji Sasaki, et al.
Cancer|March 9, 2023
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulationDaniel Nguyen, Hagop M Kantarjian, Nicholas J Short, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 9, 2026
Comprehensive Cytogenomic Profiling of T-Lymphoblastic Leukemia by Optical Genome Mapping, Karyotyping and Next Generation SequencingGuilin Tang, Alexandra Reynolds, Farhad Ravandi-Kashani, et al.
American Journal of Hematology|December 24, 2024
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic DesignationJayastu Senapati, Hagop M Kantarjian, Fadi G Haddad, et al.
American Journal of Hematology|April 12, 2022
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsKunhwa Kim, Marina Konopleva, Courtney D DiNardo, et al.
Cancer|July 13, 2021
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclaxKunhwa Kim, Abhishek Maiti, Sanam Loghavi, et al.
Pageof 35